Neurocrine biosciences receives breakthrough therapy designation from u.s. food and drug administration for crinecerfont in congenital adrenal hyperplasia

Company today also provided updates on r&d portfolio and strategy at investor event  crinecerfont new drug application submission planned in 2024 nbi-'770, an oral nmda nr2b negative allosteric modulator, entering phase 2 for the treatment of major depressive disorder advancing largest portfolio of muscarinic compounds in clinical development top-line phase 2 data readouts for five programs anticipated in 2024 including nbi-'568, an m4 agonist, for the treatment of schizophrenia san diego , dec. 5, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced it received breakthrough therapy designation from the u.s. food and drug administration (fda) for crinecerfont in congenital adrenal hyperplasia. the company also provided updates on its r&d portfolio and strategy at its analyst day, held in new york.
NBIX Ratings Summary
NBIX Quant Ranking